Latest News

Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease
Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Disease

April 1st 2025

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease.

Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement

April 1st 2025

Marcel Botha, 10XBeta
Balancing Cost-Efficiency with the Need for Domestic Manufacturing

April 1st 2025

Stock.adobe.com
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services

April 1st 2025

Emerging Biopharma Launches: Strategizing in Today’s Global Market

A look at the current landscape and how young companies can set the stage for product launch.

 A look at the current landscape and how young companies can set the stage for product launch.

Conference Coverage

View All
JPM25: Oncology Outlook for 2025
JPM25: Oncology Outlook for 2025

January 20th 2025

Stock.adobe.com
NVIDIA Announces Pharma Partnerships to Expand AI

January 15th 2025

Stock.adobe.com
Moderna Details Product Pipeline and Finances Ahead of JP Morgan Presentation

January 14th 2025

Stock.adobe.com
Biohaven Details Pipeline Update At JP Morgan Conference

January 14th 2025

Latest Videos
Podcasts
Peter Ax, UpScriptHealth
Jennifer Butler

All News